At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
DMB-I (Dimebon) +1 moredrug
Likely dose
DMB-I (Dimebon) 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Randomized Double-blind Placebo-controlled Three-arm Parallel-group Clinical Study to Evaluate the Efficacy and Safety of DMB-I in the Treatment of Dementia Associated With Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating DMB-I (Dimebon) and Placebo for Alzheimer Disease and Dementia of Alzheimer Type. Completed, enrolled 133 participants across 7 sites.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Dementia of Alzheimer Type
CountriesRussia
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartDec 2023
First PostedMar 2024
Primary CompletionJan 2025
Study CompletionJan 2025
TodayJul 2026
First PostedMar 5, 2024
Enrollment StartDec 27, 2023
Primary CompletionJan 13, 2025
Study CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 2.3 years ago
Interventions
DMB-I (Dimebon)drug
20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
Placeboother
20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)